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database. Twenty-two FDA-approved candidate drugs shifted the 
transcriptome similarly to ADSC treatment; and are thereby 
promising for RF treatment. Drug screening revealed that 
candidates which upregulate lipid metabolism or 
gluconeogenesis decreased collagen production and/or secretion 
by TGF-B stimulated fibroblasts.  
Conclusions: ADSC transplantation may be an effective 
treatment for the reversal of RF via metabolic reprogramming. 
Through pharmacogenomics analysis, we identified FDA 
approved drugs with potential to be repurposed for the 
treatment of RF based on their potential to induce metabolic 
alterations similar to ADSCs. Our data highlights the importance 
of metabolic dysregulation in the pathogenesis of RF and the 
importance of targeting these pathways in reversing RF. 
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Purpose: The mutational landscape of anal cancers has not been 
well studied. The purpose of this study was to perform the first 
analysis characterizing the types and frequencies of mutations in 
anal cancers from patients treated with radical 
chemoradiotherapy (CRT) using comprehensive next-generation 
sequencing (NGS). 
Methods and Materials: Pre-treatment formalin-fixed, paraffin-
embedded anal cancer specimens from 30 patients treated with 
radical CRT for anal cancer at a single tertiary institution were 
evaluated. Ninety percent of cases were squamous cell cancers. 
M:F ratio was 1:2.3; median patient age was 56 years (range: 34-
80): 47% (n = 14) had T2 disease. Tumour DNA was extracted and 
assayed for 50 oncogenes and tumour suppressor genes using the 
Ampliseq Cancer Hot Spot Panel (CHPv2) on the Ion PGM using a 
316v2 chip. Mean depth of target coverage was 1005X. 
Bioinformatic analysis was performed using Torrent Suite 
Software version 5.03. Variants from reference hg19 were called 
using variant Caller plugin 5.03.5 and annotated with Ion 
Reporter Software 5.0. All variants were manually reviewed 
using Broad Institute’s Integrative Genomics Viewer. Mutational 
status was determined and associated with HPV status. 
Results: Twenty-five of 30 cases (83%) were evaluable for full 
mutational analysis. The most common mutation identified was 
PIK3CA (4/25 of cases, 16%); 75% (3/4) were in exon 9. Overall, 
Pi3K/AKT/mTOR pathway activating mutations were seen in 24% 
(6/25 of cases). Other mutations were very rare: FBXW7 (n = 1, 
4%), p53 (n = 1, 4%), IDH1 (n = 1, 4%). One tumour had NRAS 
mutation; notably all other MAPK pathway genes were wild-type. 
Twenty-one of 25 cases were HPV sub-typed; 90% (19/21) were 
positive for high-risk HPV. Only p53 mutation was associated with 
HPV negative status. 
Conclusions: Pi3K/AKT/mTOR activating mutations were the 
most frequently observed in patients with anal cancer treated 
with CRT. Anal cancers have targetable mutations, making them 
amenable for consideration of therapeutics such as Pi3K and 
EGFR inhibitors. Validation with a larger data set will be 
undertaken to confirm these findings, and to determine their 
association with clinical outcome parameters. 
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Purpose: The immune microenvironment within tumours is 
critical to oncogenesis, cancer progression, and radiotherapy 
(RT) efficacy. Immunohistochemistry (IHC) is a convenient and 
inexpensive method by which to characterize the immune 
infiltrates in pathology samples. However, manually reading 
multiple IHC stains on tissue microarrays (TMA) is labor intensive 
and subject to bias. Our objective is to apply computer image 
analysis tools to localize and quantify immune markers in oral 
cavity squamous cell carcinoma (OCSCC) samples and determine 
their prognostic implications. 
Methods and Materials: A 91-patient OCSCC TMA was stained for 
the markers: CD3, CD4, CD8, FOXP3, IDO, and PD-L1. Tissue 
Studio (Definiens AG, Munich, Germany) was used to enumerate 
the number of marker-positive cells and to quantify the staining 
intensity for IDO and PD-L1. Cell populations were assigned to 
stromal or epithelial (tumour) compartments according to a mask 
derived from a pan-cytokeratin stain using a custom Matlab 
script. Automated methods were validated against manual tissue 
segmentation, cell count and stain intensity quantification. 
Univariate associations of cell counts and stain intensities with 
smoking status, TNM stage, overall survival (OS), and disease-
free survival (DFS) were determined. 
Results: 80.6% (737/910) of TMA cores were suitable for analysis, 
39.8% (35/88) of patients had a known never-smoker history, and 
34.1% (31/91) of patients were treated with RT. Comparison of 
automated to manual tissue segmentation showed good 
agreement (Kappa coefficient range: 0.61- 0.75). Automated and 
manual cell counts and stain intensities were highly correlated 
(Pearson correlation coefficient range: 0.46 - 0.91, p < 0.001 for 
all). Individual cell counts and stain intensities within the 
stromal, epithelial, or combined compartments did not display 
significant association with stage, OS or DFS in the set of all 
patients and in the subset of patients who received RT (p ≥ 0.05). 
Compared to never-smokers, current and ex-smokers had an 
increased density of FOXP3 cells in the epithelial compartment 
(OR 12.49, p = 0.06), and stronger PD-L1 stain intensity in both 
epithelial and stromal compartments (OR 4.54, p = 0.08; OR 6.58, 
p = 0.05); these results were confirmed by manual scores. 
Conclusions: Computer-assisted image analysis can be used for 
robust quantification of cellular populations by IHC. Our 
automated methods show that current and ex-smokers have 
higher density of FOXP3 cells in the epithelial compartment and 
have more intense PD-L1 staining in both epithelial and stromal 
compartments. This result is validated with manual IHC scoring. 
This proof-of-principle study demonstrates the utility of 
computer-assisted image analysis for high-throughput 
assessment of multiple IHC markers on TMAs, with potential 
implications for studies on prognostic and predictive biomarkers.  
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Purpose: Early studies have suggested a correlation between 
fluorodeoxyglucose-positron emission tomography (FDG-PET) 
uptake and epidermal growth factor receptor (EGFR) mutation 
status in patients with non-small cell lung cancer (NSCLC). 
Results from these few studies are conflicting and limited by 
small subject numbers. The purpose of this study was to 
determine if such a correlation exists in a large population using 
standardized diagnostic protocols. 
Methods and Materials: A retrospective review was conducted 
of patients with metastatic non-squamous, non-neuroendocrine, 
NSCLC who had EGFR mutation testing and FDG-PET imaging 
between March 2010 and March 2012. All patients had FDG-PET 
imaging at a central facility using the same scanning protocol. 
Data was collected on the maximum standardized uptake value 
(SUVmax) of the primary lung tumour. EGFR mutation testing was 
done at a central lab using a rapid polymerase chain reaction-
based detection technique. Patients were divided into EGFR 
mutation positive (EGFR+) and EGFR wild type (WT) cohorts. 
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Results: There were 153 patients: 45 (29%) EGFR+ and 108 (71%) 
EGFR WT. The median age was 66 years (range, 38-88). The 
population was composed of 38 (25%) Asian ethnicity, 54 (35%) 
never-smokers, and 97 (63%) female sex. The maximal diameter 
of the primary tumour on PET imaging was no different between 
the two EGFR cohorts (mean 4.0 versus 4.0 cm; p = 0.9). The 
SUVmax ranged from 1.1 to 28.9. There was no difference in 
SUVmax between EGFR+ and EGFR WT cohorts (mean 10.4 versus 
10.6; p = 0.9). There was a significant correlation between larger 
tumour size and higher SUVmax (r = 0.47; p < 0.01). Median 
survival was significantly longer for the EGFR+ cohort (28.4 
versus 14.0 months; p = 0.02). On multivariate analysis, when 
accounting for tumour size, SUVmax was not a significant factor 
for survival (p = 0.8). 
Conclusions: In our study there was no correlation between FDG-
PET uptake and EGFR mutation status in patients with metastatic 
NSCLC. The SUVmax cannot be used to predict EGFR mutation 
status or survival. 
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Purpose: Decades of reported experience with low dose rate 
penile brachytherapy have demonstrated local tumour control 
rates and penile preservation of 70-85% at 5-10 years with 
acceptable side effects. Manual source loading is not available in 
most centres in North America so there is a need to explore the 
transition to high-dose rate (HDR) automated afterloading for 
treatment delivery. Dose homogeneity parameters and 
fractionation schemes need to be developed and validated. 
Methods and Materials: Prior experience in interstitial 
template-based penile brachytherapy using either manually 
loaded Ir-192 wire or Pulse Dose Rate after-loading was the basis 
for transitioning to an HDR treatment schema using Varian 
GammaMed. Templates with 15-18 mm spacing designed for LDR 
brachytherapy were found to be not ideal for HDR delivery. 
Spacing was initially 17 mm but was decreased sequentially to 9 
mm. A new design of template was created with holes drilled 
every 3 mm so that inter-plane and inter-needle spacing could 
be generally 9 mm but increased to 12 around the urethra. Four 
patients had a 3-plane implant and two patients had 2 planes. 6-
13 catheters were used. Fractionation was 4200/12 for three 
patients, 4500/12, 5300/17 and 3840/12 for one patient each, 
with fraction sizes of 3.12-3.75 Gy, given bid six hours apart. PTV 
ranged from 4 to 57 cc, median V100: 96% (88-99), V125 75% (40-
98), V150 42% (18-89), V200 16.8% (4.7-32). 
Results: From November 2009 to December 2012 six patients 
with biopsy-proven SCC of the glans penis received HDR 
interstitial brachytherapy. Age range 33-77, Stage T1:2 and T2: 
4, pN0:1, cN0: 5, Grade was MD in five and PD in one. Median 
follow up is 55 months (31-73). All six patients are NED, although 
one patient with local and regional failure was salvaged with 
partial penectomy and left groin dissection. Toxicity was 
considerable. Five patients experienced painful necrosis with 
four requiring Hyperbaric oxygen treatment. One of these 
subsequently had partial penectomy for recurrence; the other 
four eventually healed. Three patients had severe meatal 
stenosis, one requiring a temporary suprapubic tube for 10 
months (now resolved) and one requiring a permanent perineal 
urostomy. Two patients remain potent. Toxicity was related to 
greater needle spacing, larger fraction size, larger PTV volume 
and excessive inhomogeneity. 9-12 mm is now considered ideal 
spacing, with fraction size close to 3 Gy, and with V125 ~ 40%, 
V150~20% and V200 ~5% . The final patient, whose dosimetry 
followed these parameters, was the only one who was 
complication free but also had the smallest PTV. Whether 
following these dosimetric guidelines will permit safe 
implantation of larger volumes remains to be determined. 
Conclusions: HDR penile brachytherapy is effective and can be 
delivered safely (as evidenced by two recent reports from 
Sharma et al. and Kellas-Sleczka et al.) but attention must be 
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Purpose: To estimate the rate of biochemical recurrence in 
prostate cancer treated with intraoperatively planned, low dose 
rate, prostate brachytherapy using an automated delivery system 
(IO-LDRB). 
Methods and Materials: Patients treated with IO-LDRB as a single 
modality treatment for low or low-tier intermediate-risk 
prostate cancer at three Canadian centres between December 
1997 and August 2015 were pooled for analysis. Retrospective or 
prospective databases were maintained at each centre. For this 
analysis the datasets were amalgamated and analyzed using the 
R programming language build 3.1.3 (www.r-project.org). 
Shapiro-Wilks tests of normality, descriptive statistics and 
Kaplan-Meier survival estimates of biochemical relapse-free 
survival (bRFS) were employed for analysis. 
Results: 3286 patients with a median follow up of 44 months (0.0 
- 212.8) and median biochemical follow up of 40.0 months were 
analyzed. Median age for treated patients was 65 (42-84) years. 
In these patients, median initial PSA was 5.6 ng/mL (0.03 – 23.8), 
2390 (74%) were T1 and 862 (26%) were T2, and initial Gleason 
Sum was 6 in 2383 (73%) and 7 in 810 (25%). Most patients had 
low volume disease: median % positive biopsy tissue 5.0% (0.1-
90.0), normal gland volumes: median 34.2cc (10.9 – 77.8) and 
few urinary symptoms: median pre-implant AUA was 5 (0 -33). 
387 (11.8%) of patients received hormones for a median of 3.0 
months (0.5-32.1) prior to implant. Median seed activity was 
0.437 mCi (0.10 – 0.68), D90 was 186.7 Gy (97.0 – 273.0) and V100 
was 99.37% (60.52 – 100.0). In follow up, median last PSA value 
was 0.13 (0.0 – 901.0) and available in 3192 patients. Biochemical 
failure was observed in 139 patients (5.8%) and median time to 
failure was 44.0 months (0.0 – 218.8). Five- and 10-year 
predicted bRFS were 96% and 86%, respectively. Seventy-four 
deaths were observed from all causes and of those, no death was 
attributable to prostate cancer. 
Conclusions: This is the largest cohort of patients treated with 
IO-LDRB and demonstrates it to be an effective treatment option 
for patients with low and low-tier intermediate-risk prostate 
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Purpose: EEC is a rare disease entity with only a handful of 
patients diagnosed every year at most large centres treating 
esophageal cancer. Standard treatments for EEC include 
endoscopic mucosal resection, surgery (S) or chemoradiation 
(CRT). Patients are often not candidate for S or CRT because of 
their comorbidities or for EMR because of extent of tumour. 
Brachytherapy in these instances can give high doses of RT locally 
to the tumour. We present our experience using Radical 
Brachytherapy (RBT) alone in EEC. 
